Orforglipron as an adjunct treatment for obesity or overweight with co-morbidities

Orforglipron is in clinical development for the treatment of adults living with obesity or overweight with weight-related comorbidities. Overweight and obesity are typically defined by a body mass index (BMI) over 25 and 30, respectively. This is commonly caused by excessive calorie intake, particularly from high-fat and high-sugar foods, along with genetic and environmental factors. In the UK, about 1 in 4 adults are obese, leading to serious health conditions and a life expectancy reduced by three to ten years. For some people, lifestyle and behavioural changes alone may not help. Existing medicines may be taken orally, or via an injection. There is a particular need for other effective oral treatments that would increase uptake and acceptability amongst those people living with obesity.